Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 7c; Initiates Talks with Japan for Voclosporin Phase 1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 7c; Initiates Talks with Japan for Voclosporin Phase 1

Aurinia Pharmaceuticals (AUPH): EOP2 Meeting Results Were Better Than Could Have Been Hoped For - HC Wainwright

November 7, 2016 7:52 AM EST

H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) noting the FDA intends to permit a single Phase 3 trial in support of a voclosporin NDA for LN.

The analyst views this as a major win for Aurinia,... More